iprism® SX

SINGLE USE
SURGICAL
GONIOSCOPIC LENS

OPTIMIZING INTRAOPERATIVE

Control and Visibility

The new i*prism® SX* provides exceptional clarity with expanded views of all angle structures and enhanced design characteristics, including integrated stabilization features.

i*prism® SX* delivers precise lens handling during intraoperative gonioscopy procedures – all in a convenient single-use format.

Small, lightweight handle is designed to be held in either hand, with optimized ergonomics delivering outstanding balance and ease of use in every procedure. And the short handle length prevents interference with the microscope or advanced microscope attachments.

Innovative biconic optic offers a 1.25 magnified view of angle structures and an overall wide view of the anterior chamber for crystal-clear visibility and insight into all angle structures.

Lens dimensions are designed for expanded incision access.

Gentle stabilization features integrated into the gonioprism center the view and provide dependable, steady control.

Alignment guides enable confident stent placement by optimizing positioning and clock hour spacing.

Single-use, sterile device is conveniently packaged and ready to use, with no need for cleaning, sterilization, or disinfection; just dispose of the i*prism SX* after the procedure.

See reverse side for ordering information

i*prism*® *SX*

The clear choice for optimizing iStent *inject* Trabecular Micro-Bypass procedures

iStent inject *is a groundbreaking solution for patients with glaucoma.*

- **Optimized Outflow:** *Two multi-directional stents designed to restore natural outflow*
- **Clinically Proven:** *Significant IOP reduction across a wide range of clinical studies*[1,2]
- **Procedural Elegance:** *Predictability and precision to meet the needs of your practice*
- **Proven Safety:** *Safety profile similar to cataract surgery alone*[1]

i*prism SX* Specifications

Lens Material: **PMMA**	Image Mag: **1.0 Horizontal, 1.25 Vertical**	Static Field of View: **150°**
Contact Surface Diameter: **8.7mm**	Handle Length: **41mm**	

Order Number

i*prism SX* Single Use Gonioprism, 5-pack: **SX5**

ORDERING INFORMATION

800-GLAUKOS (452-8567) • CustomerService@glaukos.com • glaukos.com

REFERENCES: 1. iStent *inject*® Trabecular Micro-Bypass System: Directions for Use, Part # 45-0176. 2. Hengerer FH. Personal experience with second-generation trabecular micro-bypass stents in combination with cataract surgery in patients with glaucoma: 3-year follow-up. ASCRS 2018 Presentation.

INDICATION FOR USE. The iStent *inject*® Trabecular Micro-Bypass System Model G2-M-IS is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma. **CONTRAINDICATIONS.** The iStent *inject* is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. **WARNINGS.** Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. **MRI INFORMATION.** The iStent *inject* is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details. **PRECAUTIONS.** The surgeon should monitor the patient postoperatively for proper maintenance of IOP. The safety and effectiveness of the iStent *inject* have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated IOP > 24 mmHg or unmedicated IOP < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents. **ADVERSE EVENTS.** Common postoperative adverse events reported in the randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%). CAUTION: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

i*prism SX* DIRECTIONS FOR USE:

See *iprism SX* package insert for detailed instructions

Glaukos Corporation
229 Avenida Fabricante • San Clemente, CA • 92672 • USA
tel 800-GLAUKOS (452-8567) • fax 949-367-9838 • Glaukos.com

GLAUKOS®

CE
2797